Results 131 to 140 of about 15,220 (305)

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. [PDF]

, 2013
OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly
AMATO, Marco Calogero, CIRESI, Alessandro, GIORDANO, Carla, GUARNOTTA, Valentina, Lo Castro, F   +4 more
core   +1 more source

CABERGOLINE IN PRACTICAL MAMMOLOGY

Medical Council, 2016
Abnormal increase in prolactin hyperprolactinemia is one of the main signs of hypothalamic-pituitary-ovarian dysfunction. Consequently, the effect of dopamine on lactophores is attenuated resulting in their persistent hyperplasia and formation of functionally active microand macro-adenomas followed by an even greater prolactin level increase. According
I. V. Vysotskaya, T. Depuis, V. P. Letyagin   +2 more
openaire   +3 more sources

Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report

Journal of Medical Case Reports, 2019
Background Prolactinomas are tumors of the pituitary gland that usually respond very well to treatment with cabergoline. Resistance to cabergoline is very rare, but when it occurs, it is a difficult problem to resolve if the tumor is inoperable.
Luiz Augusto Casulari, Lucas Faria de Castro, Iruena Moraes Kessler, José Luiz Mendonça, Maria de Fátima Magalhães Gonzaga   +4 more
doaj   +1 more source

Managing Cushing's disease: the state of the art. [PDF]

, 2014
Cushing's disease is a rare chronic disease caused by a pituitary adenoma, which leads to excess secretion of adrenocorticotropic hormone (ACTH). The over-production of ACTH leads to hyperstimulation of the adrenal glands and a chronic excess of cortisol,
Boscaro M, Casanueva FF, COLAO, ANNAMARIA, FERONE, DIEGO   +3 more
core   +1 more source

High variability in baseline urinary free cortisol values in patients with Cushing's disease [PDF]

, 2013
Objective Twenty-four-hour urinary free cortisol (UFC) sampling is commonly used to evaluate Cushing's syndrome. Because there are few data on UFC variability in patients with active Cushing's disease, we analysed baseline UFC in a large patient ...
Biller, B. M. K., Colao, A., Findling, J. W., Grp, PBS, Gu, F., Maldonado, M., Newell-Price, J., Petersenn, S., Salgado, L. R., Sen, K.   +9 more
core   +3 more sources

A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline

Journal of Clinical Endocrinology and Metabolism, 2018
Context Cabergoline is first line treatment for most patients with lactotrope pituitary tumors and hyperprolactinemia. Its use at high-dose in Parkinson's disease has largely been abandoned, because of its association with the development of a ...
C. Stiles, Eugene T Tetteh-Wayoe, J. Bestwick, R. Steeds, W. Drake   +4 more
semanticscholar   +1 more source

Giant prolactinoma: case report and review of literature [PDF]

, 2013
“Invasive giant prolactinoma” is a large prolactinoma (>4 cm in dimension) presenting with serum prolactin levels of >1000 ng/dL and mass related clinical symptoms.
Bagher Larijani, Hamidreza Aghaei Meybodi, Masoud Rahmanian, Mohammad-reza Mohajeri-Tehrani   +3 more
core   +2 more sources

Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline

Indian Journal of Endocrinology and Metabolism, 2016
Introduction: Though hypoadiponectinemia and leptin resistance have been proposed as potential factors for weight gain in patients with hyperprolactinemia (HPL), the effects of HPL and cabergoline on these adipocyte-derived hormones are not clear.
Nazir Ahmad Pala, Bashir Ahmad Laway, Raiz Ahmad Misgar, Zaffar Amin Shah, Tariq A Gojwari, Tariq A Dar   +5 more
doaj   +1 more source

Medical treatment of prolactinomas. [PDF]

, 2011
Prolactinomas, the most prevalent type of neuroendocrine disease, account for approximately 40% of all pituitary adenomas. The most important clinical problems associated with prolactinomas are hypogonadism, infertility and hyposexuality.
A Barlier, A Beckers, A Chattopadhyay, A Ciccarelli, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Di Sarno, A Di Sarno, A Klibanski, A Liuzzi, A Saveanu, A Wakil, A Zárate, AG Lania, AI McCormack, AM Colao, Annamaria Colao, AP Heaney, BM Biller, C Di Somma, C Ferrari, C Rasmussen, C Wang, CY Choong, D Cheung, D Dallabonzana, D McCall, DA De Luis, DA Sisam, DG Johnston, DG Johnston, E Delgrange, E Delgrange, E Delgrange, E Valassi, EJ Lee, F Andersohn, F Bogazzi, F Bogazzi, FF Casanueva, G Raverot, G Schettini, G Zada, GA Kaltsas, HE Turner, I Shimon, I Shimon, J Gorski, J Kharlip, J Schlechte, J Verhelst, J Webster, JC Williams, JJ Orrego, JK Devin, JM Wilson, JP Singh, JS Bevan, JW van't Verlaat, K Thapar, K Thapar, KJ Gräf, L Vilar, LB Nachtigall, LC Tan, LD George, LJ Hofland, M Biswas, M De Rosa, M De Rosa, M De Rosa, M Esteller, M Giusti, M Kars, M Kars, M Lafeber, M Muratori, M Ono, M Rocheville, M Steiger, MC Koppelman, MD Bronstein, ME Molitch, ML Vance, MP Gillam, MP Gillam, MS Huda, N Herring, OM Dekkers, P Fainstein Day, P Lancellotti, P Moriondo, PG Crosignani, PU Freda, R Homburg, R Schade, R Zanettini, RB Rothman, S Cannavò, S Ekeblad, S Karunakaran, S Mohammed, S Vallette, SG Ren, Silvia Savastano, SW Lamberts, SW Lamberts, T Mindermann, T Sabuncu, T Tan, V Goffin, VG Rasmussen, VQ Passos, W Winkelmann, WJ Jeffcoate, WS Maxson, Y Greenman   +131 more
core   +1 more source

Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation [v1; ref status: indexed, http://f1000r.es/2jm]

F1000Research, 2014
We present a case of a 21 year old male patient diagnosed with a 2.2 cm prolactin-secreting adenoma in contact with the optic chiasm. The patient was treated with up to 6mg/week of cabergoline (total cumulative dose 814 mg) and developed mild ...
Chris G. Yedinak, Shirley McCartney, Troy H. Dillard, Kevin S. Wei, Maria Fleseriu   +4 more
doaj   +1 more source